[A21-119] Cabozantinib (renal cell carcinoma) - Addendum to Commission A21-49
Last updated 21.10.2021
Project no.:
A21-119
Commission:
Commission awarded on 08.09.2021 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adult patients with treatment-naive advanced renal cell carcinoma
Result of dossier assessment:
Unchanged after addendum:
- Adults with favourable risk profile (IMDC score 0): added benefit not proven.
- Adults with intermediate (IMDC score 1-2) or unfavourable risk profile (IMDC score ≥ 3): added benefit not proven.
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A21-49 | Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2021-10-21 A G-BA decision was published.